Psyence Biomedical Ltd. (Nasdaq: PBM) ('Psyence BioMed” or the 'Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today ...
GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...
MAIA Pharmaceuticals, Inc. today announced a strategic collaboration with Asahi Kasei Pharma Corp., under which MAIA will advance Teribone™ (teriparatide) for the treatment of osteoporosis in the ...
DHL Group has announced major steps to strengthen its Life Sciences & Healthcare (LSH) logistics capabilities with an expanded dedicated Airfreight Cold ...
Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...
DOVER, DE, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- The global pharmaceutical supply chain is currently ...
In an interview with Moneycontrol, Saraf also highlighted that founders of new-age businesses have now come to a point that they understand what it takes to have a sustainable performance in the ...
Opinion
Sri Lanka’s pharmaceutical crossroads: A call for quality, structural reform and industry dialogue
In the complex ecosystem of national healthcare, the pill a patient swallows is the final link in a long, often invisible chain of science, manufacturing logistics and regulation. ..
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate ...
The last remaining nuclear arms pact between Russia and the United States is set to expire Thursday, removing any caps on the two largest atomic arsenals for the first time in more than a half-century ...
As 2026 gets underway, Johnson & Johnson (J&J) is navigating an inflection point that involves balancing a maturing internal pipeline with evolving external pressures on pricing, policy, and ...
Two weeks after launch, 91% of people had confirmed that they had completed the training. That level of visibility simply wasn’t possible for us before.” — Daniel Burgess, Aerogen Pharma SAN MATEO, CA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results